THE HOME FOR BIOPHARMA LAUNCH LEADERS TO REVOLUTIONISE LAUNCH STRATEGY & MANAGEMENT FROM CLINICAL DEVELOPMENT INTO POST-LAUNCH COMMERCIAL SUCCESS

2 - 3 December, 2025 | UK

DOWNLOAD THE PREVIOUS EVENT GUIDE

BECOME A 2025 SPONSOR

Troels Sørensen

Global Head Clinical Practice Boehringer Ingelheim

Troels Sørensen has over 25 years of experience in the pharmaceutical industry with a unique broad profile across gene therapy, biologic, and small molecule specialty care, executing customer-facing and leadership roles in Research, Clinical Operations, Medical Affairs, Sales, Marketing and Commercial Asset/Portfolio evaluation. His passion is equitable population health attainment through the integration of public and private sectors of health systems by the development of common language, measures, and goals along the tactic to impact continuum. He devised the Target Population Output (TPO) measurement, a common tool for public and private stakeholders to align population health and business goals. TPOs have been implemented and refined since 2020. In 2023 TPOs were introduced publicly in the context of the Harvard Health System Innovation Lab’s Strategic Public Private Partnership framework, and in 2024 this was presented, by Harvard, at the World Economic Forum, Davos, in a session hosted by them, Novartis and Novo Nordisk. As global head of Clinical Practice at Boehringer-Ingelheim, Troels continues to work on practical and pragmatic solutions for alignment and goal setting within the pharmaceutical industry to facilitate partnership and integration with health systems. He leads global Medical Affairs Partnerships, Implementation Science and TPO teams. Based in Basel, Switzerland, Troels, has worked for several pharmaceutical companies including Roche, Johnson & Johnson, UCB, AstraZeneca, Takeda and Novartis. He is an alumnus of the European Schools system, Oxford University, the British Medical Research Councils’ National Institute for Medical Research (now The Francis Crick Institute) and Warwick Business School.

Pharma Launch Excellence Summit Main Conference Day 1: Tuesday 3rd December

11:30 AM Roundtable Discussion: Health System and Market Strengthening: Alignment, Partnering and Integration for Launch Readiness

Setting the scene: The Centrality of Partnerships for Launch readiness 5 min

Chair : Troels Sørensen - Global Head Clinical Practice, Boehringer Ingelheim

Talk 1 : Target Population Outputs (TPOs) – is the market leady for launch? 7 min

Troels Sørensen – Head of Global Clinical Practice, Boehringer Ingelheim

Talk 2 : Evidence is the product – is the product launch ready ? 7 min

Laura Wallace – Head of Global Integrated Evidence - Boehringer Ingelheim

Talk 3: Engagement and Strategic PPPs at government level: market shaping for launch and uptake of innovations 7 min

Lena Lymperopoulou - Global Policy Executive, ex Novartis / GSK. Founder of the World Economic Forum Strategic PPPs initiative

Talk 4: Partnerships at health body and regional level: Access and launch readiness 7 min

Danny Moore - Strategic Account Director – Novartis

Talk 5: Partnerships at departmental level: Transforming Field medical to impact accountable launch leaders 7 min

Helen Kane – Global Medical Affairs and Field Medical Affairs Executive - ex-Novarts/Roche/Celgene. Founder of One MSL.

Panel discussion and questions 20 min

· Focus on the capabilities required by each respective function

3:30 PM Presentation/Case Study: Strategic Pre-Launch Planning: Quantifying Market Readiness with Target Population Outputs (TPOs)

Effective pre-launch planning goes beyond product readiness; current best standard of care provided by health systems must be maximised through optimised referral paths and access to current best standard of care. Only then is unmet need identified and innovative medicine contribution clarified. Target Population Outputs (TPOs) are short-term measures of health system effectiveness, and thus market readiness and market size. They are common units of value to both public and private health system stakeholders being utilisable for both population health and business forecasting. This enables tactical focus and opens doors for early investment sharing with health systems through strategic public-private partnerships. TPOs bring:

• Prioritisation: Deliver cross-functional clarity on tactical prioritisation accountable to tangible external impact linked to business forecast assumptions.

• Course correction: Directs useful activity metric and KPI development directly linked to business goals enabling effective impact analysis and course correction.

• Partnerships: Facilitates early collaboration with healthcare systems stakeholders to achieve common goals by sharing tactics and reducing investment costs.

Check out the incredible speaker line-up to see who will be joining Troels.

Download The Latest Agenda

In Partnership With :

QUESTIONS?

Address: IQPC Ltd, 129 Wilton Road,
London SW1V 1JZ
Telephone: 44 (0) 207 368 9300
Fax: 44 (0) 207 368 9301
Email: enquire@iqpc.co.uk